Welcome to the first Sienna Cancer Diagnostics
investor update since our listing in August.
We will provide updates when applicable
to keep you informed of our growth, and
execution of plans. Read More >
The Bladder Cancer Diagnostic Market
The first application of Sienna’s IVD test
is as an adjunct to urine cytology to assist
in the diagnosis of bladder cancer. Urine cytology
is the standard non-invasive test to investigate
whether a patient may have bladder cancer.
Sienna estimates there are approximately 1.5
million urine cytology tests performed annually
in the United States alone. Therefore, the
worldwide market for our test presents a substantial
opportunity. More >
Q&A with Mark Rees
PhD, VP of Advanced Diagnostics, StatLab Medical Products
Dr Mark Rees has served as Vice President
Advanced Diagnostics at StatLab since January
2014. Mark’s current role involves the development
and implementation of the Company’s strategic
plan for its new product line of Advanced Diagnostics.
We recently sat down with Mark and asked him
how Sienna’s product fit into StatLab’s growth
strategy and how our product is being received
by pathologists in the US. Read Q&A >
What We Do and Why We Exist
We are a medical technology company that develops
and commercialises novel diagnostic tests for
the pathology laboratory market. The initial
product developed and brought to market by
Sienna is the first in-vitro diagnostic (IVD)
test for detection of hTERT, a component of
the cancer-related biomarker, telomerase. While
telomerase is now well recognised and understood,
there has never been a clinical diagnostic
test available to detect its presence in specific
cells of interest. Read More >
IIR Research Report Puts 31 Cent Target on Sienna
Last month, Independent Investment Research
(IIR) initiated coverage on Sienna. The report
recognises Sienna as the first company to develop
an IVD product for the detection of hTERT.IIR
assigned Sienna a target price of $0.31, on
a valuation range up to $0.81, with the high-end
of the valuation range based on more aggressive
market penetration assumptions. Read Report >
StatLab Distribution
In order to gain the fastest possible sales
traction in the US market and minimise direct
costs, it was determined that a supply and
distribution partner model would provide the
optimal solution. StatLab Medical Products,
our exclusive distribution partner in the United
States, manages the sales, marketing and support
of our IVD test in the US. The StatLab team
has been promoting Sienna’s hTERT test to the
US pathology laboratory market since around
March 2017. Initial interest has been positive
with several laboratories having already commenced
their own in-house evaluation of the product.
Read More >
Appointment of Exclusive Distributor for Denmark and Sweden
In September, Sienna appointed Axlab A/S as
our exclusive distribution partner for Denmark
and Sweden, in accordance with our plan to
broaden and accelerate the global rollout of
its IVD test for the detection of hTERT. This
agreement provides Axlab with the right to
sell Sienna’s product to pathology laboratories
throughout those countries. Read More >
Sienna Teams up With UoM to Provide Future Innovators Hands-on Experience
We are passionate about our work at Sienna
and actively engage in the development of young
people seeking to establish careers in the
industry. An example of this engagement is
Sienna’s participation in the University of
Melbourne’s internship program, which is undertaken
by final-year Master of Biotechnology students.
Interns in the program get an insight into
how a science-based company actually operates,
and contribute in ways that provide genuine
results for the company. To understand how
and why we’re working with interns. Read More >
Sienna in The News – Recent Media Articles
To view the list of media articles in which Sienna has appeared,
Click Here >
Comment